The company manufactures and trades pharmaceutical bulk drugs and chemicals, specifically focusing on products like ferrous sulphate and cellulose powders for government and private healthcare clients.
The company lacks a durable moat, as evidenced by low and volatile ROCE (8.4%) and net margins (5.1%). While they operate in a regulated industry, they function primarily as a low-margin job-work provider and commodity trader with significant revenue concentration and dependence on related-party synergies.
Management is currently liquidating its primary Indore facility and vacant land to fund modernization and debt clearance, indicating a struggle to generate sufficient internal cash flow for maintenance and growth. Historical returns on equity are poor, and the company has prioritized survival-linked restructuring over shareholder distributions.
The investment collapsed as the company transitioned from a struggling manufacturer into a hollow shell of related-party transactions. Following the leadership vacuum after the Chairman's demise, the aggressive liquidation of core assets—including the primary Indore facility and land—to entities controlled by the promoter family effectively stripped the minority shareholders of any productive base. The remaining business, already suffering from a 45% decline in its chemical segment and poor cash conversion, failed to generate sufficient internal returns to modernize, leaving investors holding a stagnant entity with no operational leverage and depleted assets.
RichFakir rates Biofil Chemicals & Pharmaceuticals Ltd's business quality as poor — 33/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Biofil Chemicals & Pharmaceuticals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Biofil Chemicals & Pharmaceuticals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Biofil Chemicals & Pharmaceuticals Ltd's fair value is about ₹7 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →